Compare Charles River Laboratories Intl. Inc (CRL) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Extra Space Storage, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Extra Space Storage, Inc. trades at $146.41 (market cap $30.96B). The key difference: Extra Space Storage, Inc. is far larger — about 2.3× Charles River Laboratories Intl. Inc's market cap, and Extra Space Storage, Inc. pays a 4.42% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | EXR | |
|---|---|---|
Market Cap | $13.46B | $30.96B |
Sector | Health | Real Estate |
52-Week High | $282.00 | $152.85 |
52-Week Low | $145.57 | $126.67 |
Enterprise Value | $16.30B | $44.68B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
EXR trades at $146.77, up 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates, and maintains robust fundamentals with a 27.79% net income margin. Recent news highlights a 52-week high of $155.80 reached in late July 2026, though the stock has since pulled back slightly.
The outlook is mixed; solid earnings growth and a secure 4.3% dividend yield support the bull case, but high valuation multiples (P/E of 32.35) and increasing debt levels pose risks. Analyst consensus is a 'Hold' with a $157.25 price target, suggesting limited near-term upside from current levels amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
